Results 91 to 100 of about 35,347 (227)
Abstract Background and Objective Adequate blood supply remains a challenge in sub‐Saharan Africa (SSA). Malawi has a 13% shortfall in required blood supplies. Innovative recruitment and retention strategies are crucial to ensuring a sufficient number of donors and blood supply.
Princess Kaira +8 more
wiley +1 more source
ABSTRACT Objectives Severe chronic non‐communicable diseases (NCDs) place a significant burden on low‐ and middle‐income countries (LMICs), where overburdened and underprepared health systems lead to misdiagnosis, treatment delays and poor outcomes.
Chantelle Boudreaux +13 more
wiley +1 more source
A global survey of blood transfusion practices for patients with sickle cell disease
Abstract Background Sickle cell disease (SCD) affects over 7 million people globally, with blood transfusion remaining a cornerstone of management. However, contemporary transfusion practices across diverse settings remain poorly characterized. We evaluated global transfusion practices for patients with SCD to identify gaps and inform resource ...
Jeremy W. Jacobs +18 more
wiley +1 more source
Abstract Arterial shear‐mediated vasodilation is a well‐established measure of endothelial function and serves as a critical biomarker for cardiovascular disease risk. Endothelial function can be measured using a variety of experimental methodologies; however, the most widely adopted technique is ultrasound‐based flow‐mediated dilation (FMD), in which ...
Yi Zhen Bao +4 more
wiley +1 more source
Abstract figure legend Metabolic stimulation improves bioenergetics, redox state, hydration and hematologic indices of circulating erythrocytes from sickle cell mice. Retained mitochondria in circulating RBCs from sickle mice are a source of RBC ATP as mitochondria function (ETC, electron transport chain) inhibitors [rotenone, a mitochondrial complex I
Luis E. F. Almeida +4 more
wiley +1 more source
ABSTRACT Hydroxyurea (HU) is the most widely prescribed disease‐modifying treatment in sickle cell disease (SCD), though treatment responses vary due to metabolism and adherence. We examined HU blood levels and treatment response in patients with homozygous sickle cell disease (HbSS).
Sigrid van der Veen +26 more
wiley +1 more source
Background and Purpose Sickle cell disease (SCD) is a hereditary blood disorder caused by mutation of β‐globin. In SCD, haemoglobin polymerization causes red blood cells to assume a rigid sickle‐shape leading to neurovascular alterations, including development of vascular dementia – characterized by cognitive impairment and reduced cerebral perfusion ...
Julia Zaccarelli‐Magalhães +11 more
wiley +1 more source
ABSTRACT Background Sickle cell disease (SCD) is a chronic, inherited hemoglobinopathy that requires frequent hospitalization for disease‐related complications. Canadian data on inpatient care is limited. This study compared caregiver‐reported hospital experiences of children with SCD to those with cystic fibrosis (CF), a chronic, autosomal recessive ...
Hailey M. Zwicker +11 more
wiley +1 more source
ABSTRACT Objective To compare the efficacy and safety of roxarestat versus recombinant human erythropoietin (rhEPO) in the management of renal anemia in patients undergoing maintenance hemodialysis. Methods This was a prospective, open‐label, randomized controlled trial.
Lingling Chen, Junjie Zhu, Qiaonan Ge
wiley +1 more source
ABSTRACT Management of cerebral vasculopathy in sickle cell anemia (SCA) includes standard‐care, that is, chronic transfusion (CT) or hydroxyurea, and hematopoietic cell transplantation (HCT). DREPAGREFFE‐1 (December 2010/June 2013), a French multicenter trial, was the first prospective trial comparing standard‐care to match sibling donor (MSD)‐HCT in ...
Francoise Bernaudin +40 more
wiley +1 more source

